Cancer News
OncoLink Cancer News - HealthDay


FDA Approves Zydelig for Three Types of Blood Cancer

Wednesday, July 23, 2014 (Last Updated: 07/24/2014)

WEDNESDAY, July 23, 2014 (HealthDay News) -- Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia, follicular B-cell non-Hodgkin's lymphoma, and small lymphocytic lymphoma, the FDA said Wednesday in a news release.

The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said.

The drug's label will include a boxed warning that the medication could cause liver toxicity, diarrhea, hyperglycemia, elevated liver enzymes, hypertriglyceridemia, and colitis. Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash.

Zydelig is marketed by Gilead Sciences, based in Foster City, Calif.

More Information

Specialties OBGYN & Women's Health
Hematology & Oncology
Family Practice
Internal Medicine
Nursing
Pathology
Surgery

Health News Copyright © 2014 HealthDay. All rights reserved.


I Wish You Knew

Genomics & Cancer

View More







OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More